Operating Profit Margin
since 2005
Calculation
Regeneron Pharmaceuticals Inc., operating profit margin, long-term trends, calculation
| Operating profit margin | = | 100 | × | Income (loss) from operations1 | ÷ | Revenues1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2024 | 28.10% | = | 100 | × | 3,990,700) | ÷ | 14,202,000) |
| Dec 31, 2023 | 30.85% | = | 100 | × | 4,047,100) | ÷ | 13,117,200) |
| Dec 31, 2022 | 38.93% | = | 100 | × | 4,738,900) | ÷ | 12,172,900) |
| Dec 31, 2021 | 55.67% | = | 100 | × | 8,946,800) | ÷ | 16,071,700) |
| Dec 31, 2020 | 42.09% | = | 100 | × | 3,576,600) | ÷ | 8,497,100) |
| Dec 31, 2019 | 28.10% | = | 100 | × | 2,209,800) | ÷ | 7,863,400) |
| Dec 31, 2018 | 37.77% | = | 100 | × | 2,534,400) | ÷ | 6,710,800) |
| Dec 31, 2017 | 35.41% | = | 100 | × | 2,079,591) | ÷ | 5,872,227) |
| Dec 31, 2016 | 27.38% | = | 100 | × | 1,330,741) | ÷ | 4,860,427) |
| Dec 31, 2015 | 30.51% | = | 100 | × | 1,251,916) | ÷ | 4,103,728) |
| Dec 31, 2014 | 29.74% | = | 100 | × | 838,431) | ÷ | 2,819,557) |
| Dec 31, 2013 | 36.11% | = | 100 | × | 760,028) | ÷ | 2,104,745) |
| Dec 31, 2012 | 33.20% | = | 100 | × | 457,713) | ÷ | 1,378,477) |
| Dec 31, 2011 | -46.02% | = | 100 | × | (205,159) | ÷ | 445,824) |
| Dec 31, 2010 | -21.23% | = | 100 | × | (97,472) | ÷ | 459,074) |
| Dec 31, 2009 | -19.54% | = | 100 | × | (74,103) | ÷ | 379,268) |
| Dec 31, 2008 | -37.67% | = | 100 | × | (89,830) | ÷ | 238,457) |
| Dec 31, 2007 | -91.55% | = | 100 | × | (114,454) | ÷ | 125,024) |
| Dec 31, 2006 | -169.68% | = | 100 | × | (107,655) | ÷ | 63,447) |
| Dec 31, 2005 | -187.97% | = | 100 | × | (124,421) | ÷ | 66,193) |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$ in thousands
The financial data demonstrates a significant evolution in operational performance and revenues over the analyzed period. Initially, income from operations showed consistent negative values from 2005 through 2011, indicating operating losses. These losses reached their peak in 2011, recording a substantial deficit. Beginning in 2012, a positive turn is observed with income from operations becoming positive and experiencing notable growth, peaking substantially in 2021.
Revenues exhibit a strong upward trajectory from 2005 to 2024, with early growth being moderate but accelerating markedly after 2011. The revenue increase corresponds with the shift from operating losses to operating profits, signifying improved operational efficiency or market expansion. Despite some fluctuations, including a noticeable dip in 2022 compared to 2021, the general trend remains upward, reflecting overall growth in sales or service income.
The operating profit margin reveals a pronounced change in profitability dynamics. From deeply negative margins in the early years—from nearly -188% in 2005 to a negative peak around 46% in 2011—the margin turns positive and climbs significantly post-2011. Margins stabilize in a range between approximately 27% and 56% thereafter, suggesting sustained profitability and better cost management. The highest margin level occurs around 2021, coinciding with the peak in operating income, before experiencing some decline but remaining relatively strong through 2024.
- Income from Operations
- Consistently negative until 2011, reflecting operating challenges; turns positive from 2012 onward with significant growth, peaking substantially in 2021, followed by a moderate decrease but maintaining positive income through 2024.
- Revenues
- Steady increase over the entire period, with rapid growth post-2011; revenue peaks align with improvements in income from operations; minor decline in 2022, followed by recovery into 2024.
- Operating Profit Margin
- Marked improvement from highly negative margins before 2012 to strong positive margins afterwards; margins peak in 2021, indicating efficient operations and profitability, then moderately decrease but remain solid.
Overall, the data suggests successful operational turnaround around 2012, transitioning from losses to substantial operating profitability supported by robust revenue growth. The period after 2011 reflects increased scale, improved efficiency, and stronger financial health, albeit with some volatility in later years.
Comparison to Competitors
Regeneron Pharmaceuticals Inc., operating profit margin, long-term trends, comparison to competitors
| Regeneron Pharmaceuticals Inc. | AbbVie Inc. | Amgen Inc. | Danaher Corp. | Gilead Sciences Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2024 | 28.10% | 16.22% | 22.66% | 20.37% | 5.81% | 17.11% | -2.11% |
| Dec 31, 2023 | 30.85% | 23.49% | 29.35% | 21.77% | 28.24% | 16.00% | 38.83% |
| Dec 31, 2022 | 38.93% | 31.21% | 38.57% | 27.61% | 27.17% | 18.69% | 48.23% |
| Dec 31, 2021 | 55.67% | 31.89% | 31.44% | 25.35% | 36.72% | 25.57% | 36.73% |
| Dec 31, 2020 | 42.09% | 24.81% | 37.70% | 18.99% | 16.72% | 24.19% | 46.03% |
| Dec 31, 2019 | 28.10% | 39.03% | 43.57% | 18.25% | 19.38% | 17.99% | 28.77% |
| Dec 31, 2018 | 37.77% | 19.49% | 45.55% | 17.11% | 37.83% | 15.53% | 20.84% |
| Dec 31, 2017 | 35.41% | 33.99% | 45.76% | 16.48% | 55.04% | 14.19% | 4.95% |
| Dec 31, 2016 | 27.38% | 36.60% | 44.74% | 16.29% | 58.87% | 13.40% | 0.58% |
| Dec 31, 2015 | 30.51% | 32.97% | 40.44% | 16.87% | 69.03% | 13.77% | -45.23% |
| Dec 31, 2014 | 29.74% | 17.09% | 32.03% | 17.23% | 62.37% | 14.82% | -119.30% |
| Dec 31, 2013 | 36.11% | 30.14% | 32.25% | 17.13% | 41.87% | 12.30% | -74.54% |
| Dec 31, 2012 | 33.20% | 31.65% | 33.52% | 17.33% | 42.67% | 11.85% | 0.15% |
| Dec 31, 2011 | -46.02% | — | 28.19% | 16.27% | 46.77% | 10.62% | 8.07% |
| Dec 31, 2010 | -21.23% | — | 37.82% | 16.41% | 53.62% | 11.72% | -485.51% |
| Dec 31, 2009 | -19.54% | — | 38.37% | 13.79% | 54.55% | 10.38% | -602.63% |
| Dec 31, 2008 | -37.67% | — | 35.50% | 14.72% | 52.68% | 11.71% | -263.65% |
| Dec 31, 2007 | -91.55% | — | 27.81% | 15.79% | 57.98% | 10.00% | -210.94% |
| Dec 31, 2006 | -169.68% | — | 27.71% | 15.82% | -29.32% | 6.38% | -105.86% |
| Dec 31, 2005 | -187.97% | — | 40.33% | 15.84% | 61.41% | 10.01% | -93.15% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).